Further research in clinical and molecular prognostic factors in IDH-mutant gliomas are of high interest given the approval of the IDH inhibitor vorasidenib, opening new therapeutic avenues to postpone tumor recurrence and thereby adverse effects of immediate radiotherapy and/or chemotherapy [26]. This evidence concerns the gene IDH1 and central nervous system cancer.